Alzheimer's drug approval gets a mixed reception.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Couzin-Frankel J
  • Source:
    Science (New York, N.Y.) [Science] 2023 Jan 13; Vol. 379 (6628), pp. 126-127. Date of Electronic Publication: 2023 Jan 12.
  • Publication Type:
    News
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-9203 (Electronic) Linking ISSN: 00368075 NLM ISO Abbreviation: Science Subsets: MEDLINE
    • Publication Information:
      Publication: : Washington, DC : American Association for the Advancement of Science
      Original Publication: New York, N.Y. : [s.n.] 1880-
    • Subject Terms:
      Alzheimer Disease*/drug therapy ; Antibodies, Monoclonal, Humanized*/adverse effects ; Drug Approval*; Humans ; United States ; United States Food and Drug Administration
    • Abstract:
      FDA allows use of antibody despite ongoing debates over its benefits and dangers.
    • Accession Number:
      0 (Antibodies, Monoclonal, Humanized)
      12PYH0FTU9 (lecanemab)
    • Publication Date:
      Date Created: 20230112 Date Completed: 20230208 Latest Revision: 20230208
    • Publication Date:
      20231215
    • Accession Number:
      10.1126/science.adg6275
    • Accession Number:
      36634171